Mulu Z. Tesfay - Concepedia

Author

Mulu Z. Tesfay

Mayo Clinic in Arizona

Also Known As

M.Z Tesfay, Mulu Tesfay, Mulu Z. Tesfay

Publications

427

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic University of Minnesota Rochester Sylvester Comprehensive Cancer Center Regeneron (United States)

About

Mulu Z. Tesfay is an author at Mayo Clinic in Arizona specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	267
2	Immunology	4	4	267
3	Cell Biology	3	3	253
4	Pathology	2	2	216
5	Cell Signaling	1	1	37

Mulu Z. Tesfay

Publications

403

Citations

H-Index

Page 1

	Year	Citations
Eastern and Venezuelan Equine Encephalitis Viruses Differ in Their Ability To Infect Dendritic Cells and Macrophages: Impact of Altered Cell Tropism on Pathogenesis Christina L. Gardner, Crystal W. Burke, Mulu Z. Tesfay, Journal of Virology Viral PathogenesisImmunologyPathologyTheir AbilityImmunotherapy	2008	141
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target Conner Hartupee, Bolni Marius Nagalo, Chiswili Chabu, Frontiers in Immunology Tumor BiologyOncologyPancreatic CancerMedicineImmunology	2024	75
PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice Mulu Z. Tesfay, Amber C. Kirk, Elizabeth M. Hadac, Journal of Virology	2013	71
Alpha/Beta Interferon Inhibits Cap-Dependent Translation of Viral but Not Cellular mRNA by a PKR-Independent Mechanism Mulu Z. Tesfay, Jun Yin, Christina L. Gardner, Journal of Virology Viral ReplicationMx ProteinsImmunologyCellular MrnaCell Signaling	2007	37
Vesiculovirus Neutralization by Natural IgM and Complement Mulu Z. Tesfay, Arun Ammayappan, Mark J. Federspiel, Journal of Virology	2014	34
Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2 Rianna Vandergaast, Timothy S. Carey, Samantha Reiter,	2020	19
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine Kah-Whye Peng, Timothy S. Carey, Patrycja Lech, Vaccine VaccinationSars-cov-2 ImmunityVaccine DevelopmentVaccine TargetImmunology	2022	14
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, Molecular Therapy — Oncolytics	2018	12

Page 1